Food Chain and Health Research Theme



# Dietary fat composition, health and disease

#### Anne M Minihane, BSc, PhD Hugh Sinclair Human Nutrition Group University of Reading, UK



16<sup>th</sup> April 2008

© University of Reading 2007

www.reading.ac.uk

### Outline.....




- Background: Dietary fat, current recommendations, chronic disease incidence
- Dietary fat & cardiovascular disease
- Dietary fat & diabetes
- The ongoing *Trans* fatty acid saga
- Omega-3 (n-3) fatty acids metabolism
- Genetic variation and response to dietary change, personalised nutrition

Dietary fat.....needs a new PR agent!



• Fat is an essential nutrient




• Total dietary fat content and dietary fat composition mediator chronic disease risk



#### Fats (lipids) in the diet

- Consume 50-100g/day
- Triglycerides, cholesterol, phospholipids, minor fats
- 90-95% as trigylcerides







#### Important fatty acids in foods

Butyric acid	C4:0	
Caproic acid	C6:0	
Caprylic acid	C8:0	
Capric acid	C10:0	
Lauric acid	C12:0	Saturated fat (SFA)
Myristic acid	C14:0	
Palmitic acid	C16:0	
Stearic acid	C18:0	
Oleic acid	C18:1 (n-9) cis	Monounsaturared
Eladic acid	C18:1 (n-9) trans	fat (MUFA)
Erucic	C22:1 (n-9)	
Linoleic	C18:2 (n-6)	
$\alpha$ -linolenic acid	C18:3 (n-3)	Delaus estado de Cot
Arachadonic acid	C20:4 (n-6)	Polyunsaturated fat
Eicosapentaenoic acid	C20:5 (n-3)	(PUFA)
Docosahexaenoic acid	C22:6 (n-3)	

#### Fat composition of common fat sources









Mortality statistics from cardiovascular disease



% of total as CVD








#### Clinical symptoms of CVD


Impact of diabetes on cardiovascular risk







#### Obesity and diabetes 'the epidemic of the 21st century'



• Obese x 12.7 RR diabetes women, x 5.2 men

#### STRENGTH OF EVIDENCE ON DIETARY FAT AND RISK OF HRONIC DISEASE (WHO/FAO, 2003)



Evidence	Decreased risk	No relationship	Increased risk
CVD			
Convincing	LC n-3 PUFA		C14:0, C16:0
	Linoleic acid		Trans FA
Probable	$\alpha$ -linolenic acid	C18:0	
	Oleic acid		
Possible			C12:0
T 2 Diabetes			
Probable			SFA
Possible	LC n-3 PUFA		Total fat intake


#### FAO/WHO dietary fat guidelines 2003



Fat	% energy
Total fat	no specific recommendation but up to < 35% in highly active group, with high F&V Otherwise much lower
SFA PUFA n-6:n-3 PUFA MUFA Trans	<10% food energy, < 7% high risk individuals 6-10% energy 2.5:1-8:1 no specific recommendation <1%
Long chain n-3 PUFA	eat fish once or twice a week

#### Macronutrient composition of UK diet







#### National Diet & Nutrition Survey 2003

#### Physiological impact of dietary fat










#### Diabetes/obese: $\uparrow$ TG, $\uparrow$ LDL-3, $\downarrow$ HDL

#### Fat replacement strategies and impact on blood lipids





A Symposium: Effects of Dietary Fat and Carbohydrate on Plasma Lipoproteins and CVD/Sacks and Katan

**Figure 1.** Predicted changes in plasma cholesterol and triglyceride concentrations caused by 3 types of diet treatment: 30% fat (step 1), 20% low-fat, and Mediterranean. The standard Western and Mediterranean diets have 38% fat. The dietary changes are described more fully in the text. The meta-analysis of Mensink and Katan<sup>13</sup> was used for changes in dietary fatty acids and that of Clarke et al<sup>17</sup> for changes in dietary cholesterol. Note that the effects of carbohydrate on triglycerides are less if the carbohydrate comes from low-glycemic-index foods, as described in the text. HDL = high-density lipoprotein; LDL = low-density lipoprotein.

Are PUFA or MUFA a more efficacious replacement for SFA in lowering cholesterol?







FIG 2. Predicted changes in serum lipids and lipoproteins when 1% of dietary saturated fatty acids is replaced by fatty acids of a particular class or by carbohydrates under isoenergetic metabolic-ward or equivalent conditions. ■, saturated; □, monounsaturated; □, polyunsaturated; □, carbohydrate. Chol, cholesterol; TG, triglyceride.

Katan et al., 1994

Are all saturated fats 'equal' with respect to their cholesterol lowering effects




- Katan et al., 1994; Mensink et al., 2003
- Lauric (C12:0), Myristic (C14:0), Palmitic (16:0)
- No as different as originally thought



#### New focus on cholesterol ratio! Dietary fat & total:HDL-cholesterol ratio




- meta-analysis of n=60 trials
- n=1672



Mensink et al., 2003

Benefits gained from dietary fat manipulation are highly variable and dependant on your genetic makeup/gender/medication use etc

Move towards more personalised approach to the prevision of dietary advice






Sarkkinen et al., 1998

Cardiovascular benefits of fish oil fatty acids consistently demonstrated Physicians Health Study: n=22,000, 17y follow-up, Albert *et al.*, NEJM, 2002)






No evidence for benefit for CVD incidence or MI incidence

#### Why are EPA/DHA cardioprotective?





Buckley R, Shewring B, Turner R, Yaqoob P, Minihane AM. British Journal of Nutrition 2004:92:477-483.

Dolores Mesa, M, Buckley R, Minihane AM, Yaqoob P Atherosclerosis 2004;175:333-343.

- Finnegan YE, Minihane AM, Leigh-Firbank EC, Kew S, Meijer GW, Muggli R, Calder PC, Williams CM. American Journal of Clinical Nutrition 2003:77:783-95.. (3.3)
- Finnegan YE, Howarth D, Minihane AM, Kew S, Miller GJ, Calder PC, Williams CM. Plant and marine derived (n-3) polyunsaturated fatty acids do not affect blood coagulation and fibrinolytic factors in moderately hyperlipidemic humans. *J Nutrition* 2003;133:2210-2213. (3.3)
- Khan S, Minihane AM, Talmud P, Wright JW, Murphy MC, Williams CM, Griffin BA. *Journal of Lipid Research* 2002;43:979-985. (3.9)
- Minihane AM, Khan S, Leigh-Firbank EC, Talmud PJ, Wright JW, Murphy MC, Griffin BA, Williams CM. *Arteriosclerosis, Thrombosis and Vascular Biology* 2000;20:1990-7.


#### Fish oil fatty acids & blood lipids



Double-blind placebo-controlled cross over study- n=55



#### 6 x 1g capsules (50% EPA / DHA) / day or 6g olive oil/day for 6 weeks with a 12 week washout



Eicosapentaenoic acid C20:5 (n-3, cis)


COOH CH<sub>3</sub>

Griffin, Minihane et al., 1999

Docosahexaenoic acid C20:6 (n-3, cis)

#### Fish oil fatty acids & blood lipids






Minihane et al., 2000





# TG lowering was dependant on gender and apoE genotype




Minihane et al., AJCN submitted

### Fish oils improve vascular reactivity


- 25 healthy men mean age 46 (SD 18) years BMI 25.5 (SD 3.8) kg/m<sup>2</sup>
- test meals:
  - placebo oil meal (40 g mixed oil; 80:20, palm olein:soybean oil)
  - fish oil meal (31 g mixed oil and 9 g fish oil; 5.4 g EPA/DHA)













#### Recent estimated daily intakes of EPA + DHA in various countries


Country	Details	Intake of EPA+ DHA (mg/person/d)	Reference
UK	Adults, 19-64 years mean	244	Givens and Gibbs (2006)
UK	Females, 19-24 years, mean	109	Gibbs et al. (2007)
Belgium	Females, 18-39 years, mean	209	Sioen et al. (2006)
Belgium	Females, 18-39 years, median	50	Sioen <i>et al.</i> (2006)
Belgium	Children 4-6.5 years, mean	75	Sioen et al. (2007)
France	Women 45-63 years	344	Astorg et al. (2004)
Australia	Adults	143	Howe <i>et al.</i> (2006)
N. America	Adults	200	Vermunt and Zock (2007)
Mid-Europe	Adults	250	Vermunt and Zock (2007)
Northern Europe	Adults	590	Vermunt and Zock (2007)
Japan	Adults	950	Vermunt and Zock (2007)

# Alpha-linolenic acid ( $\alpha$ LNA) as a substitute for EPA/DHA Linseed/Rapeseed/Soybean as a substitute for fish oils?




- not independently?
- Burdge & Calder, Nutrition Research Reviews, 2006
- 'Overall the limited capacity for conversion to the longer-chain n-3 fatty acids, and the lack of efficacy in ameliorating CVD risk factors and inflammatory markers in man suggests than increased consumption of ALNA may be of little benefit in altering EPA+DHA status or in improving health outcomes compared with other dietary interventions'

Wang C, Harris *et al.*, **n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review.** Am J Clin Nutr. 2006 Jul;84(1):5-17.



# $\alpha$ LNA as a source of EPA/DHA: Bioconversion efficiency is poor





Burdge et al., 2003; Funnegan et al., 2003a; Finnegan et al., 2003b; Kew et al., 2003a; Kew et al., 2003b

What are the main factors which influence the efficiency of conversion of  $\alpha$ -LNA to EPA/DHA



- 1. Gender
- 2. Physiological status: Pre vs postmenopausal, pregnant vs non-pregnant??
- 3.  $\alpha$ LNA intake, LA intake, LA: $\alpha$ LNA (n-6:n-3 PUFA) ratio; altered by

change in n-6 intake change in n-3 intake

#### $\alpha$ LNA metabolism: men vs women



Conversion of $\alpha$ LNA to:-	Men	Women
EPA	4%	21%
DPA	8%	6%
DHA	<0.02%	9%
β <b>-oxidation</b>	33%	22%

Burdge et al. 2002; Burdge & Wootton 2002, 2003

#### Compromised vegan EPA/DHA status (Davis & Kris-Etherton 2003)




- Associated with compromised EPA/DHA status
- Sanders et al., 1978: EPA and DHA levels in vegans of 12-15% and 32-35% those in omnivores
- Sanders et al., 1992: Vegan infants < 30% of EPA/DHA relative to omnivores
- More compromised in vegans than vegetarians as eggs (~50mg DHA/egg) and milk a source
- n-6: n-3 PUFA ratio: < 10:1, 10:1-16:1 and 14:1-20:1 in omnivores, vegetarians and vegans
- αLNA rich oils suggested as oil source in vegetarians and vegans
   -Linseed (flaxseed) n-6:n-3 PUFA- 0.28:1
   -Rapeseed oil (canola): n-6:n-3 PUFA- 2:1
  - -Soybean: n-6:n-3 PUFA- 2:1

# Strong emerging evidence to indicate lifestyle has large impact on diabetes risk



- n= 3234 subjects with high fasting and post-load glucose
- Follow up 2.3 years

#### **Diabetes incidence**



Knowler et al. (2002) New Engl. J Med, 346, 393-403

Observation studies in humans and animal invention trials have shown that saturated fat is associated with a loss of insulin sensitivity.....




n=579 70y old men	
Fatty acid	Plasma- fatty acid insulin sensitivity correlation
C16:0	-0.24 (P<0.001)
C16:1	-0.28 (P<0.001)
C18:2	+0.26(P<0.001)
Vessby et al., 1994	

Human intervention trials to date disappointing!

#### KANWU study Vessby et al., 2001



- 162 healthy men and women
- 3 months
- SFA v MUFA rich diet
- 37% fat, 17% SFA, 14% MUFA
- 37% fat, 8% SFA, 23% MUFA
- +/- 3.6g EPA+DHA per day
- MUFA increased insulin sensitivity compared to SFA diet
- No evident in those with total fat > 37% energy
- No effect of fish oil





#### Research needs in dietary fat composition and insulin action/MS/diabetes

#### Intervention studies with following study attributes

- Compare impact of realistic alterations in total fat intake or fat composition (SFA, MUFA, PUFA ratios) on insulin action
- Use of robust measurements of insulin action
- Adequately power
- Longer intervention periods
- Healthy or early disease cohorts



www.risck.org.uk

-n=650 -6 months intervention

-<u>5 diets</u> Diet A: 38% fat, 18% SFA, 12% MUFA Diet B: 38% fat, 10% SFA, 20% MUFA Diet C: Diet B with low GI Diet D: 28% fat Diet E: Diet D with low GI

Lipgene CONSTRUCTION SIXTH FRAMEWORK SIXTH FRAMEWORK WWW.lipgene.tcd.ie

-n=480

-3 months intervention

-<u>4 diets</u> Diet A: 38% fat, 18% SFA, 12% MUFA Diet B: 38% fat, 10% SFA, 20% MUFA Diet C: 28% fat Diet D: Diet C + 1g EPA/DHA

Reading: Lovegrove, Williams, et al.,



Update on trans fatty acids and health

Position statement by the Scientific Advisory Committee on Nutrition

2007

Main conclusions of report

- •Consistent evidence TFA  $\uparrow$  CHD risk
- •Largely due to effects on LDLC and HDLC
- •Other mechanisms also likely

•Most evidence derived from epidemiological studies where range of intakes several fold higher than current intakes

Some suggestion TFA associated with diabetes
& obesity. However evidence limited
Distinct lack of information on 1-3% of dietary energy range

•Great care is needed that reformulation of fat currently underway to minimise TFA intakes do not inadvertently increase SFA intakes


#### Zupthen Elderly Study 1985, 10y follow up



Risk	of CHD	

	Trans fatty acid tertile (% of energy)			p value*
	<\$11 (n=222)	8-11-4-86 (n=223)	≫4- <del>8</del> 9 (n=222)	
Median intake (% of energy)	236	3-87	6.38	
Cases	24 (11%)	33 (14%)	44 (20%)	
Relative risks (95% CI)				
Grude	1	1-26 (0-74-2-15)	2.03(1.24 - 3.34)	0-003
Age+energy adjusted	1	1.36(0.79-2.34)	2.19 (1.32-3.62)	0-002
Fully adjusted	1	1-34 (0-76-2-37)	2 00 (2 07 - 3 75)	0-03


\*Values were obtained by modelling the median value of each pategory as a continuous variable.







# Impact of *Trans Fatty* acids on CHD risk largely due to blood lipid effects



Emerging evidence for effect of *trans* fatty acids on inflammation and endothelial function

### Closing remarks....



- Current dietary SFA intake too high- replacement with MUFA/PUFA not (refined) carbohydrates
- 'Over' focus on *trans* fats. Care must be taken did current efforts to reduce *trans* intake does not inadvertently increase SFA content of foods
- Evidence from human intervention trials to demonstrate the impact of dietary fat composition on insulin sensitivity and diabetes risk is as yet limited
- Cardioprotective effect EPA/DHA attributable to multiple mechanisms
- Further studies to investigate dose-effect relationships needs
- αLNA levels evidence of independent health benefit
- αLNA source of EPA/DHA but bioconversion poor
- Great need for better understanding of individual response to dietary fat change

#### Acknowledgements



- Christine Williams, Kim Jackson, Jan Luff, Bettina Kofler, Chris Armah, Jilly Grew-University of Reading
- Liz Miles, Philip Calder- University of Southampton
- Georg Lietz, John Mathers- University of Newcastle
- Muriel Caslake, Chris Packard, Glasgow University
- Gerald Rimbach, University of Kiel, Germany

